The relevance of the hematopoietic niche for therapy resistance in acute myeloid leukemia

The expansion of acute myeloid leukemia (AML) blasts not only suppresses normal hematopoiesis, but also alters the microenvironment. The interplay of different components of the bone marrow gives rise to altered metabolic states and activates signaling pathways which lead to resistance and impede ef...

Full description

Saved in:
Bibliographic Details
Published inInternational journal of cancer Vol. 154; no. 2; pp. 197 - 209
Main Authors Allert, Catana, Müller‐Tidow, Carsten, Blank, Maximilian Felix
Format Journal Article
LanguageEnglish
Published Hoboken, USA John Wiley & Sons, Inc 15.01.2024
Wiley Subscription Services, Inc
Subjects
Acute myeloid leukemia
Cancer
Cancer research
cell adhesion‐mediated drug resistance
Cell interactions
Clinical trials
Hematology
Hemopoiesis
Medical research
Microenvironments
niche related therapies
soluble factor‐mediated drug resistance
Targeted cancer therapy
Therapeutic targets
cell adhesion-mediated drug resistance
niche related therapies
soluble factor-mediated drug resistance
Online AccessGet full text

Cover

Abstract The expansion of acute myeloid leukemia (AML) blasts not only suppresses normal hematopoiesis, but also alters the microenvironment. The interplay of different components of the bone marrow gives rise to altered metabolic states and activates signaling pathways which lead to resistance and impede effective therapy. Therefore, the underlying processes and mechanisms represent attractive therapeutic leverage points for overcoming therapy resistance in AML. Here, we briefly discuss resistance mechanisms based on cell interactions and secreted soluble factors in the hematopoietic niche and provide an overview of niche‐related therapeutic targets currently undergoing preclinical and clinical investigation which may help improve the outcome in AML therapy.
AbstractList The expansion of acute myeloid leukemia (AML) blasts not only suppresses normal hematopoiesis, but also alters the microenvironment. The interplay of different components of the bone marrow gives rise to altered metabolic states and activates signaling pathways which lead to resistance and impede effective therapy. Therefore, the underlying processes and mechanisms represent attractive therapeutic leverage points for overcoming therapy resistance in AML. Here, we briefly discuss resistance mechanisms based on cell interactions and secreted soluble factors in the hematopoietic niche and provide an overview of niche‐related therapeutic targets currently undergoing preclinical and clinical investigation which may help improve the outcome in AML therapy.
Abstract The expansion of acute myeloid leukemia (AML) blasts not only suppresses normal hematopoiesis, but also alters the microenvironment. The interplay of different components of the bone marrow gives rise to altered metabolic states and activates signaling pathways which lead to resistance and impede effective therapy. Therefore, the underlying processes and mechanisms represent attractive therapeutic leverage points for overcoming therapy resistance in AML. Here, we briefly discuss resistance mechanisms based on cell interactions and secreted soluble factors in the hematopoietic niche and provide an overview of niche‐related therapeutic targets currently undergoing preclinical and clinical investigation which may help improve the outcome in AML therapy.
Author Müller‐Tidow, Carsten
Blank, Maximilian Felix
Allert, Catana
Author_xml – sequence: 1
  givenname: Catana
  surname: Allert
  fullname: Allert, Catana
  organization: University of Heidelberg Medical Faculty
– sequence: 2
  givenname: Carsten
  surname: Müller‐Tidow
  fullname: Müller‐Tidow, Carsten
  organization: University of Heidelberg and European Molecular Biology Laboratory (EMBL)
– sequence: 3
  givenname: Maximilian Felix
  orcidid: 0000-0002-7524-4080
  surname: Blank
  fullname: Blank, Maximilian Felix
  email: maximilianfelix.blank@med.uni-heidelberg.de
  organization: German Cancer Research Center (DKFZ)
BackLink https://www.ncbi.nlm.nih.gov/pubmed/37565773$$D View this record in MEDLINE/PubMed
BookMark eNp1kE1LxDAQhoOsuB968A9IwYseqpkm6cdRFj8RvOjBU0nTCWZtm5q0yv57s656EDwNzDzvy_DMyaSzHRJyCPQMKE3OzUqdMZ7mfIfMgBZZTBMQEzILNxpnwNIpmXu_ohRAUL5HpiwTqcgyNiPPjy8YOWzwXXYKI6ujISxesJWD7a3BwaioMyrstHWbm5P9OgS88cNXwnSRVOOAUbvGxpo6anB8xdbIfbKrZePx4HsuyNPV5ePyJr5_uL5dXtzHivGcx0mW67oSmGpQKueFSLSskaUcoOBMi1pUaQFUJ5BXEjkKyHUqGc0VZgopZwtysu3tnX0b0Q9la7zCppEd2tGXSS4oA8iChwU5_oOu7Oi68F2gigRSCPYCdbqllLPeO9Rl70wr3boEWm58l8F3-eU7sEffjWPVYv1L_ggOwPkW-DANrv9vKm_vltvKT6P_ivI
Cites_doi 10.1182/blood.V91.12.4523
10.1182/blood.2020006343
10.1016/j.stem.2014.06.020
10.1111/bjh.16456
10.1038/s41598‐017‐07848‐8
10.3389/fcell.2020.00668
10.1016/j.cyto.2012.12.023
10.1016/j.leukres.2019.106180
10.3389/fonc.2018.00369
10.1038/nm.4416
10.20517/cdr.2021.125
10.3389/fphar.2020.579068
10.1002/hon.3120
10.1182/bloodadvances.2017013391
10.1200/JCO.2019.37.15_suppl.7001
10.3390/molecules24010009
10.1182/blood.V124.21.386.386
10.1038/nbt1350
10.1182/blood‐2010‐04‐280503
10.1590/1678‐4685‐GMB‐2019‐0268
10.1182/blood‐2008‐05‐158311
10.3389/fonc.2022.899502
10.1182/blood‐2006‐05‐024844
10.1038/s41467‐020‐15817‐5
10.1002/ijc.34243
10.1182/blood.2021010721
10.1002/cncr.33338
10.1016/j.ccell.2019.01.007
10.1038/s41586‐021‐03536‐w
10.1016/j.leukres.2014.03.007
10.21037/atm‐20‐3191
10.1038/nm.2969
10.1158/1535‐7163.MCT‐16‐0719
10.3324/haematol.2017.183418
10.1016/j.stem.2017.11.006
10.1002/ar.23345
10.1038/leu.2017.82
10.1038/s41375‐022‐01696‐w
10.1158/0008‐5472.can‐03‐3693
10.1242/jcs.190991
10.1182/bloodadvances.2017007856
10.1016/bs.ctm.2015.07.002
10.1002/jcb.24755
10.1158/0008‐5472.CAN‐18‐0921
10.1038/bcj.2017.21
10.1038/s41388‐020‐1261‐0
10.3324/haematol.2020.269944
10.1038/leu.2010.214
10.1038/s41375‐023‐01846‐8
10.18632/oncotarget.21809
10.1002/1878‐0261.12640
10.1016/j.canlet.2010.03.021
10.1038/nature07639
10.1182/blood‐2016‐08‐734798
10.18632/oncotarget.9617
10.3389/fonc.2020.592733
10.1016/j.cell.2005.10.041
10.1038/s41375‐022‐01687‐x
10.3389/fonc.2020.01672
10.1038/s41375‐022‐01798‐5
10.1038/nature10783
10.1182/blood‐2008‐10‐184754
10.1074/jbc.M115.668160
10.1016/j.leukres.2021.106713
10.1186/s40364‐021‐00265‐0
10.1126/scitranslmed.3000349
10.1158/2159‐8290.CD‐21‐0692
10.1182/blood‐2011‐10‐383406
10.1038/s41392‐022‐01259‐6
10.1158/1535‐7163.MCT‐19‐0841
10.1182/blood.2021011510
10.1002/ajh.25162
10.18632/oncotarget.7911
10.3324/haematol.2016.143180
10.1002/jcp.24154
10.1158/2159‐8290.CD‐21‐1059
10.1038/s41467‐022‐30117‐w
10.1111/bjh.18513
ContentType Journal Article
Copyright 2023 The Authors. published by John Wiley & Sons Ltd on behalf of UICC.
2023 The Authors. International Journal of Cancer published by John Wiley & Sons Ltd on behalf of UICC.
2023. This article is published under http://creativecommons.org/licenses/by-nc/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
Copyright_xml – notice: 2023 The Authors. published by John Wiley & Sons Ltd on behalf of UICC.
– notice: 2023 The Authors. International Journal of Cancer published by John Wiley & Sons Ltd on behalf of UICC.
– notice: 2023. This article is published under http://creativecommons.org/licenses/by-nc/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
DBID 24P
WIN
NPM
AAYXX
CITATION
7T5
7TO
7U9
H94
K9.
7X8
DOI 10.1002/ijc.34684
DatabaseName Wiley-Blackwell Open Access Collection
Wiley Online Library Journals
PubMed
CrossRef
Immunology Abstracts
Oncogenes and Growth Factors Abstracts
Virology and AIDS Abstracts
AIDS and Cancer Research Abstracts
ProQuest Health & Medical Complete (Alumni)
MEDLINE - Academic
DatabaseTitle PubMed
CrossRef
AIDS and Cancer Research Abstracts
ProQuest Health & Medical Complete (Alumni)
Immunology Abstracts
Virology and AIDS Abstracts
Oncogenes and Growth Factors Abstracts
MEDLINE - Academic
DatabaseTitleList AIDS and Cancer Research Abstracts
MEDLINE - Academic
CrossRef
PubMed
Database_xml – sequence: 1
  dbid: 24P
  name: Wiley-Blackwell Open Access Collection
  url: https://authorservices.wiley.com/open-science/open-access/browse-journals.html
  sourceTypes: Publisher
– sequence: 2
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1097-0215
EndPage 209
ExternalDocumentID 10_1002_ijc_34684
37565773
IJC34684
Genre reviewArticle
Journal Article
Review
GrantInformation_xml – fundername: Wilhelm‐Sander‐Stiftung
  funderid: 2021.145.1
– fundername: Deutsche Forschungsgemeinschaft
  funderid: MU1328/18‐1; MU1328/23‐1
– fundername: Deutsche Krebshilfe
  funderid: 70113908
– fundername: José Carreras Leukämie‐Stiftung
  funderid: 04R/2022
– fundername: Deutsche Krebshilfe
  grantid: 70113908
– fundername: Deutsche Forschungsgemeinschaft
  grantid: MU1328/23-1
– fundername: Wilhelm-Sander-Stiftung
  grantid: 2021.145.1
– fundername: Deutsche Forschungsgemeinschaft
  grantid: MU1328/18-1
– fundername: José Carreras Leukämie-Stiftung
  grantid: 04R/2022
GroupedDBID ---
-~X
.3N
.GA
05W
0R~
10A
1L6
1OB
1OC
1ZS
24P
33P
3SF
3WU
4.4
4ZD
50Y
50Z
51W
51X
52M
52N
52O
52P
52R
52S
52T
52U
52V
52W
52X
5GY
5VS
66C
702
7PT
8-0
8-1
8-3
8-4
8-5
8UM
930
A01
A03
AAESR
AAEVG
AAHHS
AANLZ
AAONW
AAXRX
AAZKR
ABCQN
ABCUV
ABIJN
ABJNI
ABLJU
ABOCM
ABPVW
ABQWH
ABXGK
ACAHQ
ACCFJ
ACCZN
ACFBH
ACGFO
ACGFS
ACGOF
ACIWK
ACMXC
ACPOU
ACPRK
ACXBN
ACXQS
ADBBV
ADBTR
ADEOM
ADIZJ
ADKYN
ADMGS
ADOZA
ADXAS
ADZMN
ADZOD
AEEZP
AEGXH
AEIGN
AEIMD
AENEX
AEQDE
AEUQT
AEUYR
AFBPY
AFFPM
AFGKR
AFPWT
AFRAH
AFZJQ
AHBTC
AHMBA
AIACR
AIAGR
AITYG
AIURR
AIWBW
AJBDE
ALAGY
ALMA_UNASSIGNED_HOLDINGS
ALUQN
AMBMR
AMYDB
ATUGU
AZBYB
AZVAB
BAFTC
BFHJK
BHBCM
BMXJE
BROTX
BRXPI
BY8
C45
CS3
D-6
D-7
D-E
D-F
DCZOG
DPXWK
DR2
DRFUL
DRMAN
DRSTM
DU5
EBS
F00
F01
F04
F5P
FUBAC
G-S
G.N
GNP
GODZA
H.X
HBH
HGLYW
HHY
HHZ
HZ~
IH2
IX1
J0M
JPC
KBYEO
KQQ
L7B
LATKE
LAW
LC2
LC3
LEEKS
LH4
LITHE
LOXES
LP6
LP7
LUTES
LYRES
MEWTI
MK4
MRFUL
MRMAN
MRSTM
MSFUL
MSMAN
MSSTM
MXFUL
MXMAN
MXSTM
N04
N05
N9A
NF~
NNB
O66
O9-
OIG
OK1
OVD
P2P
P2W
P2X
P2Z
P4B
P4D
PQQKQ
Q.N
Q11
QB0
QRW
R.K
RIWAO
ROL
RWI
RX1
RYL
SUPJJ
TEORI
UB1
UDS
V2E
V8K
V9Y
W2D
W8V
W99
WBKPD
WHWMO
WIB
WIH
WIJ
WIK
WIN
WJL
WOHZO
WQJ
WRC
WUP
WVDHM
WWO
WXI
WXSBR
XG1
XPP
XV2
ZZTAW
~IA
~WT
EMOBN
NPM
AAYXX
CITATION
7T5
7TO
7U9
H94
K9.
7X8
ID FETCH-LOGICAL-c3484-278fdb5e6f1cc84952fade36411943f5d5b6910f218bae4e518f6a308ce7ce043
IEDL.DBID DR2
ISSN 0020-7136
IngestDate Fri Aug 16 12:07:00 EDT 2024
Thu Oct 10 18:50:41 EDT 2024
Wed Aug 14 12:34:25 EDT 2024
Sat Sep 28 08:16:36 EDT 2024
Sat Aug 24 00:55:37 EDT 2024
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 2
Keywords cell adhesion-mediated drug resistance
niche related therapies
soluble factor-mediated drug resistance
Language English
License Attribution-NonCommercial
2023 The Authors. International Journal of Cancer published by John Wiley & Sons Ltd on behalf of UICC.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c3484-278fdb5e6f1cc84952fade36411943f5d5b6910f218bae4e518f6a308ce7ce043
Notes ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
ORCID 0000-0002-7524-4080
OpenAccessLink https://proxy.k.utb.cz/login?url=https://onlinelibrary.wiley.com/doi/abs/10.1002%2Fijc.34684
PMID 37565773
PQID 2892161109
PQPubID 105430
PageCount 13
ParticipantIDs proquest_miscellaneous_2850311771
proquest_journals_2892161109
crossref_primary_10_1002_ijc_34684
pubmed_primary_37565773
wiley_primary_10_1002_ijc_34684_IJC34684
PublicationCentury 2000
PublicationDate 15 January 2024
PublicationDateYYYYMMDD 2024-01-15
PublicationDate_xml – month: 01
  year: 2024
  text: 15 January 2024
  day: 15
PublicationDecade 2020
PublicationPlace Hoboken, USA
PublicationPlace_xml – name: Hoboken, USA
– name: United States
– name: Hoboken
PublicationTitle International journal of cancer
PublicationTitleAlternate Int J Cancer
PublicationYear 2024
Publisher John Wiley & Sons, Inc
Wiley Subscription Services, Inc
Publisher_xml – name: John Wiley & Sons, Inc
– name: Wiley Subscription Services, Inc
References 2012; 481
2017; 7
2017; 8
2004; 64
2017; 1
2011; 117
2023; 37
2023; 8
2013; 61
2021; 127
2015; 76
2016; 101
2009; 113
2020; 14
2012; 18
2020; 11
2020; 10
2022; 139
2007; 109
2009; 114
2020; 19
2020; 8
2022; 200
2017; 31
2018; 8
2015; 290
2018; 2
2010; 24
2019; 24
2014; 15
2022; 36
2022; 37
2021; 593
1998; 91
2021; 110
2010; 2
2007; 25
2017; 129
2006; 124
2014; 124
2021; 9
2021; 44
2019; 35
2019; 79
2013; 228
2019; 37
2017; 23
2018; 103
2020; 39
2017; 130
2020; 189
2018; 22
2014; 115
2009; 457
2016; 7
2019; 84
2023
2023; 152
2022
2022; 5
2017; 16
2021; 138
2022; 12
2014; 38
2022; 13
2016; 299
2010; 296
2018; 93
2022; 107
2012; 119
e_1_2_9_75_1
e_1_2_9_31_1
e_1_2_9_52_1
e_1_2_9_50_1
e_1_2_9_73_1
e_1_2_9_79_1
e_1_2_9_10_1
e_1_2_9_35_1
e_1_2_9_56_1
e_1_2_9_77_1
e_1_2_9_12_1
e_1_2_9_33_1
e_1_2_9_54_1
e_1_2_9_71_1
e_1_2_9_14_1
e_1_2_9_39_1
e_1_2_9_16_1
e_1_2_9_37_1
e_1_2_9_58_1
e_1_2_9_18_1
e_1_2_9_41_1
e_1_2_9_64_1
e_1_2_9_20_1
e_1_2_9_62_1
e_1_2_9_22_1
e_1_2_9_45_1
e_1_2_9_68_1
e_1_2_9_24_1
e_1_2_9_43_1
e_1_2_9_66_1
e_1_2_9_8_1
e_1_2_9_6_1
e_1_2_9_4_1
e_1_2_9_60_1
e_1_2_9_2_1
e_1_2_9_26_1
e_1_2_9_49_1
e_1_2_9_28_1
e_1_2_9_47_1
e_1_2_9_30_1
e_1_2_9_53_1
e_1_2_9_74_1
e_1_2_9_51_1
e_1_2_9_72_1
e_1_2_9_11_1
e_1_2_9_34_1
e_1_2_9_57_1
e_1_2_9_78_1
e_1_2_9_13_1
e_1_2_9_32_1
e_1_2_9_55_1
e_1_2_9_76_1
e_1_2_9_70_1
e_1_2_9_15_1
e_1_2_9_38_1
e_1_2_9_17_1
e_1_2_9_36_1
e_1_2_9_59_1
e_1_2_9_19_1
e_1_2_9_42_1
e_1_2_9_63_1
e_1_2_9_40_1
e_1_2_9_61_1
e_1_2_9_21_1
e_1_2_9_46_1
e_1_2_9_67_1
e_1_2_9_23_1
e_1_2_9_44_1
e_1_2_9_65_1
e_1_2_9_7_1
e_1_2_9_80_1
e_1_2_9_5_1
e_1_2_9_3_1
e_1_2_9_9_1
e_1_2_9_25_1
e_1_2_9_27_1
e_1_2_9_48_1
e_1_2_9_69_1
e_1_2_9_29_1
References_xml – volume: 8
  start-page: 94569
  issue: 55
  year: 2017
  end-page: 94579
  article-title: Histone deacetylase inhibitors reduce differentiating osteoblast‐mediated protection of acute myeloid leukemia cells from cytarabine
  publication-title: Oncotarget
– volume: 114
  start-page: 1331
  issue: 7
  year: 2009
  end-page: 1339
  article-title: Suppression of CXCL12 production by bone marrow osteoblasts is a common and critical pathway for cytokine‐induced mobilization
  publication-title: Blood
– volume: 127
  start-page: 1246
  issue: 8
  year: 2021
  end-page: 1259
  article-title: BL‐8040 CXCR4 antagonist is safe and demonstrates antileukemic activity in combination with cytarabine for the treatment of relapsed/refractory acute myelogenous leukemia: an open‐label safety and efficacy phase 2a study
  publication-title: Cancer
– volume: 117
  start-page: 780
  issue: 3
  year: 2011
  end-page: 787
  article-title: Expression of ARC (apoptosis repressor with caspase recruitment domain), an antiapoptotic protein, is strongly prognostic in AML
  publication-title: Blood
– volume: 200
  start-page: 740
  year: 2022
  end-page: 754
  article-title: Transcriptomics of acute myeloid leukaemia core bone marrow biopsies reveals distinct therapy response‐specific osteo‐mesenchymal profiles
  publication-title: Br J Haematol
– volume: 189
  start-page: 815
  issue: 5
  year: 2020
  end-page: 825
  article-title: Dissecting the role of the CXCL12/CXCR4 axis in acute myeloid leukaemia
  publication-title: Br J Haematol
– volume: 296
  start-page: 65
  issue: 1
  year: 2010
  end-page: 73
  article-title: Enrichment of N‐cadherin and Tie2‐bearing CD34+/CD38‐/CD123+ leukemic stem cells by chemotherapy‐resistance
  publication-title: Cancer Lett
– volume: 7
  start-page: 20054
  issue: 15
  year: 2016
  end-page: 20067
  article-title: Anti‐apoptotic ARC protein confers chemoresistance by controlling leukemia‐microenvironment interactions through a NFkappaB/IL1beta signaling network
  publication-title: Oncotarget
– volume: 457
  start-page: 97
  issue: 7225
  year: 2009
  end-page: 101
  article-title: Detection of functional haematopoietic stem cell niche using real‐time imaging
  publication-title: Nature
– volume: 14
  start-page: 779
  issue: 4
  year: 2020
  end-page: 794
  article-title: CCL5 mediates target‐kinase independent resistance to FLT3 inhibitors in FLT3‐ITD‐positive AML
  publication-title: Mol Oncol
– volume: 130
  start-page: 2435
  issue: 15
  year: 2017
  end-page: 2446
  article-title: Talin—the master of integrin adhesions
  publication-title: J Cell Sci
– volume: 37
  start-page: 788
  issue: 4
  year: 2023
  end-page: 798
  article-title: Outcome prediction by the 2022 European LeukemiaNet genetic‐risk classification for adults with acute myeloid leukemia: an Alliance study
  publication-title: Leukemia
– volume: 93
  start-page: 1074
  issue: 8
  year: 2018
  end-page: 1081
  article-title: Very poor long‐term survival in past and more recent studies for relapsed AML patients: the ECOG‐ACRIN experience
  publication-title: Am J Hematol
– volume: 129
  start-page: 1320
  issue: 10
  year: 2017
  end-page: 1332
  article-title: Leukemic blasts program bone marrow adipocytes to generate a protumoral microenvironment
  publication-title: Blood
– volume: 15
  start-page: 365
  issue: 3
  year: 2014
  end-page: 375
  article-title: Acute myelogenous leukemia‐induced sympathetic neuropathy promotes malignancy in an altered hematopoietic stem cell niche
  publication-title: Cell Stem Cell
– volume: 10
  year: 2020
  article-title: Targeting CXCR4 in AML and ALL
  publication-title: Front Oncol
– volume: 64
  start-page: 2817
  issue: 8
  year: 2004
  end-page: 2824
  article-title: CXCR4 regulates migration and development of human acute myelogenous leukemia stem cells in transplanted NOD/SCID mice
  publication-title: Cancer Res
– volume: 10
  year: 2020
  article-title: Cadherins, selectins, and integrins in CAM‐DR in leukemia
  publication-title: Front Oncol
– volume: 79
  start-page: 1165
  issue: 6
  year: 2019
  end-page: 1177
  article-title: An ARC‐regulated IL1beta/cox‐2/PGE2/beta‐catenin/ARC circuit controls leukemia‐microenvironment interactions and confers drug resistance in AML
  publication-title: Cancer Res
– volume: 23
  start-page: 1369
  issue: 11
  year: 2017
  end-page: 1376
  article-title: The N(6)‐methyladenosine (m(6)A)‐forming enzyme METTL3 controls myeloid differentiation of normal hematopoietic and leukemia cells
  publication-title: Nat Med
– volume: 593
  start-page: 597
  issue: 7860
  year: 2021
  end-page: 601
  article-title: Small‐molecule inhibition of METTL3 as a strategy against myeloid leukaemia
  publication-title: Nature
– volume: 11
  start-page: 2042
  issue: 1
  year: 2020
  article-title: Endothelial E‐selectin inhibition improves acute myeloid leukaemia therapy by disrupting vascular niche‐mediated chemoresistance
  publication-title: Nat Commun
– volume: 7
  issue: 3
  year: 2017
  article-title: A phase 1/2 study of chemosensitization with plerixafor plus G‐CSF in relapsed or refractory acute myeloid leukemia
  publication-title: Blood Cancer J
– volume: 91
  start-page: 4523
  issue: 12
  year: 1998
  end-page: 4530
  article-title: The chemokine receptor CXCR‐4 is expressed on CD34+ hematopoietic progenitors and leukemic cells and mediates transendothelial migration induced by stromal cell‐derived factor‐1
  publication-title: Blood
– volume: 228
  start-page: 306
  issue: 2
  year: 2013
  end-page: 312
  article-title: Integrin bi‐directional signaling across the plasma membrane
  publication-title: J Cell Physiol
– year: 2022
– volume: 22
  start-page: 64
  issue: 1
  year: 2018
  end-page: 77.e6
  article-title: Inhibition of endosteal vascular niche remodeling rescues hematopoietic stem cell loss in AML
  publication-title: Cell Stem Cell
– volume: 39
  start-page: 3910
  issue: 19
  year: 2020
  end-page: 3925
  article-title: Tetraspanin CD82 drives acute myeloid leukemia chemoresistance by modulating protein kinase C alpha and beta1 integrin activation
  publication-title: Oncogene
– volume: 12
  start-page: 1106
  issue: 4
  year: 2022
  end-page: 1127
  article-title: Subversion of serotonin receptor signaling in osteoblasts by kynurenine drives acute myeloid leukemia
  publication-title: Cancer Discov
– volume: 7
  start-page: 7305
  issue: 1
  year: 2017
  article-title: Targeting primary acute myeloid leukemia with a new CXCR4 antagonist IgG1 antibody (PF‐06747143)
  publication-title: Sci Rep
– volume: 35
  start-page: 347
  issue: 3
  year: 2019
  end-page: 367
  article-title: Integrin signaling in cancer: mechanotransduction, stemness, epithelial plasticity, and therapeutic resistance
  publication-title: Cancer Cell
– volume: 139
  start-page: 3040
  issue: 20
  year: 2022
  end-page: 3057
  article-title: Critical role of Lama4 for hematopoiesis regeneration and acute myeloid leukemia progression
  publication-title: Blood
– volume: 113
  start-page: 6215
  issue: 24
  year: 2009
  end-page: 6224
  article-title: Targeting the leukemia microenvironment by CXCR4 inhibition overcomes resistance to kinase inhibitors and chemotherapy in AML
  publication-title: Blood
– volume: 19
  start-page: 1636
  issue: 8
  year: 2020
  end-page: 1648
  article-title: Combinatorial inhibition of focal adhesion kinase and BCL‐2 enhances antileukemia activity of venetoclax in acute myeloid leukemia
  publication-title: Mol Cancer Ther
– volume: 8
  start-page: 668
  year: 2020
  article-title: Acute myeloid leukemia chemo‐resistance is mediated by E‐selectin receptor CD162 in bone marrow niches
  publication-title: Front Cell Dev Biol
– volume: 481
  start-page: 457
  issue: 7382
  year: 2012
  end-page: 462
  article-title: Endothelial and perivascular cells maintain haematopoietic stem cells
  publication-title: Nature
– volume: 107
  start-page: 381
  issue: 2
  year: 2022
  end-page: 392
  article-title: Reversible switching of leukemic cells to a drug‐resistant, stem‐like subset via IL‐4‐mediated cross‐talk with mesenchymal stroma
  publication-title: Haematologica
– volume: 24
  issue: 1
  year: 2019
  article-title: Molecular repolarisation of tumour‐associated macrophages
  publication-title: Molecules
– volume: 115
  start-page: 1128
  issue: 6
  year: 2014
  end-page: 1137
  article-title: Osteoblasts protect AML cells from SDF‐1‐induced apoptosis
  publication-title: J Cell Biochem
– volume: 16
  start-page: 1133
  issue: 6
  year: 2017
  end-page: 1144
  article-title: Focal adhesion kinase as a potential target in AML and MDS
  publication-title: Mol Cancer Ther
– volume: 119
  start-page: 3917
  issue: 17
  year: 2012
  end-page: 3924
  article-title: A phase 1/2 study of chemosensitization with the CXCR4 antagonist plerixafor in relapsed or refractory acute myeloid leukemia
  publication-title: Blood
– volume: 101
  start-page: 1216
  issue: 10
  year: 2016
  end-page: 1227
  article-title: Acute myeloid leukemia cells polarize macrophages towards a leukemia supporting state in a growth factor independence 1 dependent manner
  publication-title: Haematologica
– volume: 299
  start-page: 990
  issue: 7
  year: 2016
  end-page: 998
  article-title: N‐cadherin aided in maintaining the characteristics of leukemic stem cells
  publication-title: Anat Rec
– volume: 84
  year: 2019
  article-title: Interleukin‐8 blockade prevents activated endothelial cell mediated proliferation and chemoresistance of acute myeloid leukemia
  publication-title: Leuk Res
– volume: 2
  start-page: 381
  issue: 4
  year: 2018
  end-page: 389
  article-title: Combination of the low anticoagulant heparin CX‐01 with chemotherapy for the treatment of acute myeloid leukemia
  publication-title: Blood Adv
– volume: 9
  start-page: 15
  issue: 1
  year: 2021
  article-title: Single‐cell map of diverse immune phenotypes in the acute myeloid leukemia microenvironment
  publication-title: Biomark Res
– volume: 76
  start-page: 197
  year: 2015
  end-page: 229
  article-title: Molecular basis of laminin‐integrin interactions
  publication-title: Curr Top Membr
– volume: 44
  issue: 1
  year: 2021
  article-title: Expression profiling of some acute myeloid leukemia‐associated markers to assess their diagnostic/prognostic potential
  publication-title: Genet Mol Biol
– volume: 8
  start-page: 1346
  issue: 21
  year: 2020
  article-title: Stromal cells promote chemoresistance of acute myeloid leukemia cells via activation of the IL‐6/STAT3/OXPHOS axis
  publication-title: Ann Transl Med
– volume: 5
  start-page: 380
  issue: 2
  year: 2022
  end-page: 400
  article-title: Venetoclax resistance: mechanistic insights and future strategies
  publication-title: Cancer Drug Resist
– volume: 31
  start-page: 2336
  issue: 11
  year: 2017
  end-page: 2346
  article-title: The CXCR4 inhibitor BL‐8040 induces the apoptosis of AML blasts by downregulating ERK, BCL‐2, MCL‐1 and cyclin‐D1 via altered miR‐15a/16‐1 expression
  publication-title: Leukemia
– volume: 36
  start-page: 2586
  issue: 11
  year: 2022
  end-page: 2595
  article-title: METTL3 mediates chemoresistance by enhancing AML homing and engraftment via ITGA4
  publication-title: Leukemia
– volume: 12
  year: 2022
  article-title: Targeting mitochondrial oxidative phosphorylation eradicates acute myeloid leukemic stem cells
  publication-title: Front Oncol
– volume: 124
  issue: 21
  year: 2014
  article-title: Targeting the CXCR4 pathway: safety, tolerability and clinical activity of Ulocuplumab (BMS‐936564), an anti‐CXCR4 antibody in relapsed/refractory acute myeloid leukemia
  publication-title: Blood
– volume: 7
  start-page: 40387
  issue: 26
  year: 2016
  end-page: 40397
  article-title: Integrin alphavbeta3 enhances beta‐catenin signaling in acute myeloid leukemia harboring Fms‐like tyrosine kinase‐3 internal tandem duplication mutations: implications for microenvironment influence on sorafenib sensitivity
  publication-title: Oncotarget
– volume: 1
  start-page: 1387
  issue: 18
  year: 2017
  end-page: 1397
  article-title: Interleukin‐6 levels predict event‐free survival in pediatric AML and suggest a mechanism of chemotherapy resistance
  publication-title: Blood Adv
– volume: 38
  start-page: 632
  issue: 5
  year: 2014
  end-page: 637
  article-title: N‐cadherin and Tie2 positive CD34(+)CD38(−)CD123(+) leukemic stem cell populations can develop acute myeloid leukemia more effectively in NOD/SCID mice
  publication-title: Leuk Res
– volume: 152
  start-page: 340
  issue: 3
  year: 2023
  end-page: 347
  article-title: Therapy resistance mechanisms in hematological malignancies
  publication-title: Int J Cancer
– volume: 290
  start-page: 29478
  issue: 49
  year: 2015
  end-page: 29492
  article-title: Histone deacetylase inhibitors target the leukemic microenvironment by enhancing a Nherf1‐protein phosphatase 1alpha‐TAZ signaling pathway in osteoblasts
  publication-title: J Biol Chem
– volume: 18
  start-page: 1651
  issue: 11
  year: 2012
  end-page: 1657
  article-title: Vascular niche E‐selectin regulates hematopoietic stem cell dormancy, self renewal and chemoresistance
  publication-title: Nat Med
– volume: 61
  start-page: 885
  issue: 3
  year: 2013
  end-page: 891
  article-title: Cytokine profiles in acute myeloid leukemia patients at diagnosis: survival is inversely correlated with IL‐6 and directly correlated with IL‐10 levels
  publication-title: Cytokine
– volume: 25
  start-page: 1315
  issue: 11
  year: 2007
  end-page: 1321
  article-title: Chemotherapy‐resistant human AML stem cells home to and engraft within the bone‐marrow endosteal region
  publication-title: Nat Biotechnol
– volume: 24
  start-page: 1979
  issue: 12
  year: 2010
  end-page: 1992
  article-title: The endosteal ‘osteoblastic’ niche and its role in hematopoietic stem cell homing and mobilization
  publication-title: Leukemia
– volume: 8
  start-page: 1
  issue: 1
  year: 2023
  article-title: Targeting integrin pathways: mechanisms and advances in therapy
  publication-title: Signal Transduct Target Ther
– volume: 11
  year: 2020
  article-title: The biological functions and clinical applications of integrins in cancers
  publication-title: Front Pharmacol
– volume: 109
  start-page: 786
  issue: 2
  year: 2007
  end-page: 791
  article-title: CXCR4 is a prognostic marker in acute myelogenous leukemia
  publication-title: Blood
– volume: 12
  start-page: 31
  issue: 1
  year: 2022
  end-page: 46
  article-title: Hallmarks of cancer: new dimensions
  publication-title: Cancer Discov
– volume: 8
  start-page: 369
  year: 2018
  article-title: Initial report of a phase I study of LY2510924, idarubicin, and cytarabine in relapsed/refractory acute myeloid leukemia
  publication-title: Front Oncol
– volume: 37
  issue: 15_suppl
  year: 2019
  article-title: A randomized phase II trial of CX‐01 with standard therapy in elderly patients with acute myeloid leukemia (AML)
  publication-title: J Clin Oncol
– volume: 124
  start-page: 407
  issue: 2
  year: 2006
  end-page: 421
  article-title: Signals from the sympathetic nervous system regulate hematopoietic stem cell egress from bone marrow
  publication-title: Cell
– volume: 36
  start-page: 2418
  issue: 10
  year: 2022
  end-page: 2429
  article-title: Protein tyrosine kinase 2b inhibition reverts niche‐associated resistance to tyrosine kinase inhibitors in AML
  publication-title: Leukemia
– volume: 139
  start-page: 1135
  issue: 8
  year: 2022
  end-page: 1146
  article-title: Phase 1/2 study of uproleselan added to chemotherapy in patients with relapsed or refractory acute myeloid leukemia
  publication-title: Blood
– volume: 13
  start-page: 2362
  issue: 1
  year: 2022
  article-title: Mechanism of integrin activation by Talin and its cooperation with kindlin
  publication-title: Nat Commun
– volume: 103
  start-page: 1308
  issue: 8
  year: 2018
  end-page: 1316
  article-title: Phase I trial of plerixafor combined with decitabine in newly diagnosed older patients with acute myeloid leukemia
  publication-title: Haematologica
– year: 2023
  article-title: Knockdown of let‐7b in leukemia associated macrophages inhibit acute myeloid leukemia progression
  publication-title: Hematol Oncol
– volume: 2
  issue: 17
  year: 2010
  article-title: Identification of therapeutic targets for quiescent, chemotherapy‐resistant human leukemia stem cells
  publication-title: Sci Transl Med
– volume: 138
  start-page: 1067
  issue: 12
  year: 2021
  end-page: 1080
  article-title: CD44 loss of function sensitizes AML cells to the BCL‐2 inhibitor venetoclax by decreasing CXCL12‐driven survival cues
  publication-title: Blood
– volume: 110
  year: 2021
  article-title: Combination of dociparstat sodium (DSTAT), a CXCL12/CXCR4 inhibitor, with azacitidine for the treatment of hypomethylating agent refractory AML and MDS
  publication-title: Leuk Res
– volume: 37
  start-page: 560
  year: 2022
  end-page: 570
  article-title: Microenvironmental CXCL12 deletion enhances Flt3‐ITD acute myeloid leukemia stem cell response to therapy by reducing p38 MAPK signaling
  publication-title: Leukemia
– ident: e_1_2_9_49_1
  doi: 10.1182/blood.V91.12.4523
– ident: e_1_2_9_52_1
  doi: 10.1182/blood.2020006343
– ident: e_1_2_9_14_1
  doi: 10.1016/j.stem.2014.06.020
– ident: e_1_2_9_51_1
  doi: 10.1111/bjh.16456
– ident: e_1_2_9_72_1
  doi: 10.1038/s41598‐017‐07848‐8
– ident: e_1_2_9_37_1
  doi: 10.3389/fcell.2020.00668
– ident: e_1_2_9_60_1
  doi: 10.1016/j.cyto.2012.12.023
– ident: e_1_2_9_64_1
  doi: 10.1016/j.leukres.2019.106180
– ident: e_1_2_9_76_1
  doi: 10.3389/fonc.2018.00369
– ident: e_1_2_9_32_1
  doi: 10.1038/nm.4416
– ident: e_1_2_9_29_1
  doi: 10.20517/cdr.2021.125
– ident: e_1_2_9_20_1
  doi: 10.3389/fphar.2020.579068
– ident: e_1_2_9_17_1
  doi: 10.1002/hon.3120
– ident: e_1_2_9_77_1
  doi: 10.1182/bloodadvances.2017013391
– ident: e_1_2_9_79_1
  doi: 10.1200/JCO.2019.37.15_suppl.7001
– ident: e_1_2_9_16_1
  doi: 10.3390/molecules24010009
– ident: e_1_2_9_80_1
  doi: 10.1182/blood.V124.21.386.386
– ident: e_1_2_9_11_1
  doi: 10.1038/nbt1350
– ident: e_1_2_9_55_1
  doi: 10.1182/blood‐2010‐04‐280503
– ident: e_1_2_9_56_1
  doi: 10.1590/1678‐4685‐GMB‐2019‐0268
– ident: e_1_2_9_47_1
  doi: 10.1182/blood‐2008‐05‐158311
– ident: e_1_2_9_62_1
  doi: 10.3389/fonc.2022.899502
– ident: e_1_2_9_46_1
  doi: 10.1182/blood‐2006‐05‐024844
– ident: e_1_2_9_36_1
  doi: 10.1038/s41467‐020‐15817‐5
– ident: e_1_2_9_3_1
  doi: 10.1002/ijc.34243
– ident: e_1_2_9_66_1
  doi: 10.1182/blood.2021010721
– ident: e_1_2_9_74_1
  doi: 10.1002/cncr.33338
– ident: e_1_2_9_22_1
  doi: 10.1016/j.ccell.2019.01.007
– ident: e_1_2_9_34_1
  doi: 10.1038/s41586‐021‐03536‐w
– ident: e_1_2_9_39_1
  doi: 10.1016/j.leukres.2014.03.007
– ident: e_1_2_9_63_1
  doi: 10.21037/atm‐20‐3191
– ident: e_1_2_9_35_1
  doi: 10.1038/nm.2969
– ident: e_1_2_9_67_1
  doi: 10.1158/1535‐7163.MCT‐16‐0719
– ident: e_1_2_9_71_1
  doi: 10.3324/haematol.2017.183418
– ident: e_1_2_9_12_1
  doi: 10.1016/j.stem.2017.11.006
– ident: e_1_2_9_40_1
  doi: 10.1002/ar.23345
– ident: e_1_2_9_73_1
  doi: 10.1038/leu.2017.82
– ident: e_1_2_9_33_1
  doi: 10.1038/s41375‐022‐01696‐w
– ident: e_1_2_9_50_1
  doi: 10.1158/0008‐5472.can‐03‐3693
– ident: e_1_2_9_26_1
  doi: 10.1242/jcs.190991
– ident: e_1_2_9_61_1
  doi: 10.1182/bloodadvances.2017007856
– ident: e_1_2_9_24_1
  doi: 10.1016/bs.ctm.2015.07.002
– ident: e_1_2_9_41_1
  doi: 10.1002/jcb.24755
– ident: e_1_2_9_58_1
  doi: 10.1158/0008‐5472.CAN‐18‐0921
– ident: e_1_2_9_69_1
  doi: 10.1038/bcj.2017.21
– ident: e_1_2_9_31_1
  doi: 10.1038/s41388‐020‐1261‐0
– ident: e_1_2_9_59_1
  doi: 10.3324/haematol.2020.269944
– ident: e_1_2_9_7_1
  doi: 10.1038/leu.2010.214
– ident: e_1_2_9_2_1
  doi: 10.1038/s41375‐023‐01846‐8
– ident: e_1_2_9_43_1
  doi: 10.18632/oncotarget.21809
– ident: e_1_2_9_54_1
  doi: 10.1002/1878‐0261.12640
– ident: e_1_2_9_38_1
  doi: 10.1016/j.canlet.2010.03.021
– ident: e_1_2_9_6_1
  doi: 10.1038/nature07639
– ident: e_1_2_9_9_1
  doi: 10.1182/blood‐2016‐08‐734798
– ident: e_1_2_9_23_1
  doi: 10.18632/oncotarget.9617
– ident: e_1_2_9_18_1
  doi: 10.3389/fonc.2020.592733
– ident: e_1_2_9_13_1
  doi: 10.1016/j.cell.2005.10.041
– ident: e_1_2_9_30_1
  doi: 10.1038/s41375‐022‐01687‐x
– ident: e_1_2_9_48_1
  doi: 10.3389/fonc.2020.01672
– ident: e_1_2_9_53_1
  doi: 10.1038/s41375‐022‐01798‐5
– ident: e_1_2_9_8_1
  doi: 10.1038/nature10783
– ident: e_1_2_9_70_1
  doi: 10.1182/blood‐2008‐10‐184754
– ident: e_1_2_9_44_1
  doi: 10.1074/jbc.M115.668160
– ident: e_1_2_9_78_1
  doi: 10.1016/j.leukres.2021.106713
– ident: e_1_2_9_10_1
  doi: 10.1186/s40364‐021‐00265‐0
– ident: e_1_2_9_4_1
  doi: 10.1126/scitranslmed.3000349
– ident: e_1_2_9_45_1
  doi: 10.1158/2159‐8290.CD‐21‐0692
– ident: e_1_2_9_75_1
– ident: e_1_2_9_68_1
  doi: 10.1182/blood‐2011‐10‐383406
– ident: e_1_2_9_19_1
  doi: 10.1038/s41392‐022‐01259‐6
– ident: e_1_2_9_28_1
  doi: 10.1158/1535‐7163.MCT‐19‐0841
– ident: e_1_2_9_25_1
  doi: 10.1182/blood.2021011510
– ident: e_1_2_9_65_1
  doi: 10.1002/ajh.25162
– ident: e_1_2_9_57_1
  doi: 10.18632/oncotarget.7911
– ident: e_1_2_9_15_1
  doi: 10.3324/haematol.2016.143180
– ident: e_1_2_9_21_1
  doi: 10.1002/jcp.24154
– ident: e_1_2_9_5_1
  doi: 10.1158/2159‐8290.CD‐21‐1059
– ident: e_1_2_9_27_1
  doi: 10.1038/s41467‐022‐30117‐w
– ident: e_1_2_9_42_1
  doi: 10.1111/bjh.18513
SSID ssj0011504
Score 2.4896905
SecondaryResourceType review_article
Snippet The expansion of acute myeloid leukemia (AML) blasts not only suppresses normal hematopoiesis, but also alters the microenvironment. The interplay of different...
Abstract The expansion of acute myeloid leukemia (AML) blasts not only suppresses normal hematopoiesis, but also alters the microenvironment. The interplay of...
SourceID proquest
crossref
pubmed
wiley
SourceType Aggregation Database
Index Database
Publisher
StartPage 197
SubjectTerms Acute myeloid leukemia
Cancer
Cancer research
cell adhesion‐mediated drug resistance
Cell interactions
Clinical trials
Hematology
Hemopoiesis
Medical research
Microenvironments
niche related therapies
soluble factor‐mediated drug resistance
Targeted cancer therapy
Therapeutic targets
Title The relevance of the hematopoietic niche for therapy resistance in acute myeloid leukemia
URI https://onlinelibrary.wiley.com/doi/abs/10.1002%2Fijc.34684
https://www.ncbi.nlm.nih.gov/pubmed/37565773
https://www.proquest.com/docview/2892161109
https://search.proquest.com/docview/2850311771
Volume 154
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3NaxUxEB9qD-JFrZ-rtUTx4GVfN5tksw9P0g9qQRGxUEFYkuwE1ra7xff2UP96J9kPqUUQbwubIbuZmeQ3mckvAK8LjUpYy1NvhEklLWGpXWKoBFBYS-k8-sj2-bE4OpHHp-p0A95OZ2EGfoh5wy14Rpyvg4Mbu9r9TRrafHcLIYsycIFyoUM51_7nmToqAJ2RgTlLKRArJlahLN-dJa-vRTcA5nW8Ghecw3vwbfrUoc7kbNGv7cL9_IPF8T__5T7cHYEoezdYzhZsYPsAbn8YU-0P4SsZEAs3qsQaAdZ5RlCRRYrX7rJrwtlH1oY6Ukawlw3HuK5IYBUAaZBoWmZcv0Z2cYXnXVOzc-zP8KIxj-Dk8ODL3lE63sOQOiFLmea69LVVWHjuXEkRVe5NjaKQnC-l8KpWtiDU4QktWIMSFS99YURWOtQOMykew2bbtfgUmAtpTlXnmXVaSuON4RRBuZLMAoVamgReTRqpLge6jWogVs4rGqQqDlIC25OuqtHjVhUFjjmhV54tE3g5vyZfCQkQ02LXhzaK5jCuNU_gyaDjuRehQwJYiwTeRE39vfvq_fFefHj2702fw52c0FDYu-FqGzbXP3p8QWhmbXfgVi4_7UTj_QUh2vBU
link.rule.ids 315,783,787,1378,11576,27938,27939,46066,46308,46490,46732
linkProvider Wiley-Blackwell
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV3Pb9UwDLbGkGAXxG8KAwLiwKWsaZy0lbigieltbBOHTRqnKk0dqbC10_beYf89TtpXNCEkbpUaK5KdxJ_t-AvAB1OQVk0jU2-VTZFdWNpUFG4CaGoRnScf2T6PzeIUD8702QZ8XvfCjPwQc8It7Ix4XocNHhLSO39YQ7uf7pNCU-IduIsGq_BwQ47f5xoCQ52JgzlLORQza16hLN-ZRW97o78g5m3EGl3O3kN4MGFF8WU07iPYoP4x3DuaquFP4AfbWIRHT2IZXwxeMJoTkYV1uBy60J4o-nDVUzAyFWOn1Q0LXAfMGCS6Xli3WpK4uKHzoWvFOa1-0UVnn8Lp3teT3UU6PZWQOoUlpnlR-rbRZLx0ruSgJ_e2JWVQygqV161uDAMDzw69sYSkZemNVVnpqHCUoXoGm_3Q0wsQLlQidZtnjSsQrbdWcpDjSrYcKV3ZBN6vVVZfjowY9ch9nNes1zrqNYHttTLraVNc1xzb5QwwZVYl8G7-zcs51ChsT8MqjNF8zMiikAk8H40wz6KKUKMtVAIfo1X-PX29f7AbP17-_9C3cH9xcnRYH-4ff3sFWzmDl5BqkXobNpdXK3rN4GPZvIlr7DcvvNLk
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV3NS-UwEB_8APEi6u5q_YzLHvZSbZqk7cOTqA8_dsXDCu6ppOkE6kf70PcO_vdO0r6KiOCt0AyBmUzmN5nMLwC_khSVKAoeWi10KCmEhcUA3U0AhaWUxqL1bJ9XydmNvLhVtzNwOO2Fafkh-gM35xl-v3YOPirtwRtpaHVn9oVMMjkL89LBcEfrLK_7EgIhnY6COQopE0umtEJRfNCLvg9GHxDme8DqI85wGZY6qMiOWtuuwAzWq7DwtyuGf4P_ZGLm3jzxVXzWWEZgjnkS1mbUVK47kdXupicjYMraRqsXEnh2kNFJVDXTZjJG9viCD01Vsgec3ONjpb_DzfD03_FZ2L2UEBohMxnGaWbLQmFiuTEZ5Tyx1SWKRHI-kMKqUhUJ4QJL8bzQKFHxzCZaRJnB1GAkxQ-Yq5sa14EZV4hUZRwVJpVSW605KddkZDgUaqAD-DlVWT5qCTHylvo4zkmvuddrAFtTZeadTzznlNrFhC95NAhgr_9Nq9mVKHSNzcSNUbTL8DTlAay1RuhnEakr0aYigN_eKp9Pn59fHPuPja8P3YWF65Nh_uf86nITFmOCLu6ghastmBs_TXCboMe42PFL7BUEqtIN
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=The+relevance+of+the+hematopoietic+niche+for+therapy+resistance+in+acute+myeloid+leukemia&rft.jtitle=International+journal+of+cancer&rft.au=Allert%2C+Catana&rft.au=M%C3%BCller%E2%80%90Tidow%2C+Carsten&rft.au=Blank%2C+Maximilian+Felix&rft.date=2024-01-15&rft.issn=0020-7136&rft.eissn=1097-0215&rft.volume=154&rft.issue=2&rft.spage=197&rft.epage=209&rft_id=info:doi/10.1002%2Fijc.34684&rft.externalDBID=n%2Fa&rft.externalDocID=10_1002_ijc_34684
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0020-7136&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0020-7136&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0020-7136&client=summon